

COMMENTARY

Targeting glutamine metabolism in *PIK3CA* mutant colorectal cancers



Xiujing Feng, Yujun Hao, Zhenghe Wang*

Department of Genetics and Genome Sciences and Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA

Received 26 August 2016; accepted 3 September 2016
Available online 10 September 2016

Abstract We recently reported that *PIK3CA* mutant colorectal cancers (CRCs) are addicted to glutamine through up-regulation of glutamate pyruvate transaminase 2 (GPT2). A GPT2 inhibitor suppresses in vivo growth of *PIK3CA* mutant, but not wild-type, CRCs. This study indicates that targeting glutamine may be an effective approach to treat CRCs with *PIK3CA* mutations. Copyright © 2016, Chongqing Medical University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Metabolic reprogramming is a hallmark of cancer.¹ It has long been known that most cancer cells are dependent on glutamine to grow. Although glutamine is a non-essential amino acid, it is a required supplement for culturing cancer cells. In addition to being used as a building block for protein, glutamine can also be utilized as a fuel source to replenish the tricarboxylic acid (TCA) cycle. In this process, glutamine is first converted to glutamate by glutaminases (GLSs), followed by conversion to α -ketoglutarate (α -KG), a TCA cycle intermediate (Fig. 1). The conversion from glutamate to α -KG is mediated by either transaminases or glutamate dehydrogenases. Recent studies showed that many oncogenes and tumor suppressor genes are involved in glutamine metabolism. *PIK3CA*, which encodes the p110 α

catalytic subunit of phosphatidylinositol 3-kinase α (PI3K α), is the most frequently mutated oncogene in human cancers including 20–30% of colorectal cancers (CRCs).^{2,3} However, whether mutant *PIK3CA*/p110 α reprograms cancer metabolism was an important unaddressed question.

Using isogenic CRC cell lines with either the wild type (WT) or mutant alleles of *PIK3CA* knocked out, we demonstrated that *PIK3CA* mutations render CRCs more addicted to glutamine, but not glucose.⁴ To our knowledge, this is the first study to demonstrate that specific oncogenic mutations render cancer cells differentially sensitive to glutamine deprivation. Although it has been previously shown that WT *KRAS* regulates glutamine metabolism in pancreatic cancers,⁵ it is not clear that oncogenic *KRAS* mutations render cancer cells more sensitive to glutamine deprivation. Moreover, our study clearly demonstrated that *KRAS* mutations do not make colorectal cancers more dependent on glutamine, because isogenic *KRAS* mutant and WT CRC clones do not show differential sensitivity to glutamine deprivation.⁴

* Corresponding author.

E-mail address: zxw22@case.edu (Z. Wang).

Peer review under responsibility of Chongqing Medical University.




Fig. 1 Oncogenic *PIK3CA* mutations reprogram glutamine metabolism by up-regulating GPT2. As a fuel source, glutamine is first converted to glutamate and then α -KG to replenish the tricarboxylic acid (TCA) cycle. Oncogenic p110 α mutant protein reprograms glutamine metabolism through upregulation of GPT2. A pan-aminotransferase inhibitor AOA suppresses xenograft tumor growth of *PIK3CA* mutant, but not wild type (WT), CRCs. GLS: glutaminase; GPT2: glutamate pyruvate transaminase 2; α -KG: α -ketoglutarate; AOA: aminooxyacetate.

Mechanistically, mutant *PIK3CA*/p110 α up-regulates mitochondrial glutamate pyruvate transaminase 2 (GPT2) and therefore converts more glutamate to α -KG to replenish the TCA cycle,⁴ which generates more ATP and macromolecules to sustain rapid tumor growth. Although AKT is a well-known downstream mediator of the PI3K signaling, mutant p110 α up-regulates GPT2 gene expression by an AKT independent pathway. Mutant p110 α activates RSK2 kinase through PDK1.⁴ Activated RSK2 then phosphorylates ATF4 at the serine residue 245, which in turn recruits the deubiquitinase USP8 and protects ATF4 from ubiquitin-mediated degradation.⁴ Accumulation of ATF4 enhances GPT2 gene expression. Therefore, our study revealed a novel p110 α –PDK1–RSK2–ATF4–GPT2 signaling axis that reprograms glutamine metabolism.

Our study has important therapeutic implications. Despite huge efforts made by both pharmaceutical companies and academic institutions in last ten years, only a couple of p110 α -specific inhibitors have been developed. Early clinical trials of the Novartis p110 α -specific inhibitor, BYL719, indicate that BYL719 alone induced partial responses in cancer patients harboring *PIK3CA* mutations.⁶ Recent studies showed that cancers quickly develop resistance to BYL719 by loss of *PTEN* or up-regulation of *AXL*.⁷ Therefore, alternative approaches are urgently needed to target *PIK3CA* mutations in patients. We demonstrated that aminooxyacetate (AOA), a compound that targets glutamine metabolism by blocking conversion of glutamate to α -KG (Fig. 1), effectively inhibits xenograft tumor growth of four colorectal cancer cell lines harboring *PIK3CA* mutations.⁴ In contrast, AOA has no effect on the growth of xenograft tumors established from two colorectal cancer

cell lines with WT *PIK3CA*.⁴ Although AOA is a pan-aminotransferase inhibitor, our data clearly demonstrate that the tumor inhibitory effect of AOA on *PIK3CA* mutant xenografts is indeed on-target to GPT2, because GPT2 knockdown cells grow much slower in nude mice and these tumors are insensitive to AOA treatment.⁴ It is conceivable that a GPT2-specific inhibitor could be more potent and less toxic. Our current effort is devoted to develop potent and specific GPT2 inhibitor by performing a high throughput compound screening campaign and chemically modifying the lead compound AOA.

Lastly, our study suggest that *PIK3CA* mutations may serve as a predictive biomarker for drugs that target glutamine metabolism. Predictive markers are critical tools to guide successful clinical trials and effective treatment of cancer patients. For example, in lung cancer, only patients with *EGFR* mutations respond to EGFR-inhibitor treatment, whereas in colon cancers acquired *KRAS* mutations predict resistance to anti-EGFR antibody therapies. These markers provide valuable tools for guiding the choice of cancer therapies. Increasing evidence indicates that targeting glutamine metabolism could be an effective cancer therapy. Many preclinical studies demonstrated that targeting glutamine metabolism effectively inhibits tumor growth of a variety of human cancers.⁸ Several compounds that target glutamine metabolism pathways are under development. In fact, phase I clinical trials have been undertaken for a compound (CB-839) that inhibits glutaminase.⁹ A key question is how to better select cancer patients to be treated with drugs that target glutamine metabolism. Our unpublished data demonstrated that CB-839 also inhibits xenograft tumor growth of *PIK3CA* mutant CRCs, but not *PIK3CA* WT CRCs, suggesting that *PIK3CA* mutations may serve as a biomarker to predict patients who respond to drugs targeting glutamine metabolism.

In summary, implications of our study are three-fold: (1) shed new lights into the mechanisms by which *PIK3CA* mutations drive colorectal tumorigenesis through reprogramming glutamine metabolism; (2) identify GPT2 as a drug target for CRCs with *PIK3CA* mutations; and (3) indicate *PIK3CA* mutation as a predictive biomarker for drugs targeting glutamine metabolism. Future studies are warranted to pursue these exciting directions.

Acknowledgement

This work is supported by National Institutes of Health grants R01CA196643, R01CA127590, P50CA150964 and P30 CA043703.

References

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144:646–674.
2. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the *PIK3CA* gene in human cancers. *Science*. 2004;304:554.
3. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. *Nature*. 2014;505:495–501.

4. Hao Y, Samuels Y, Li Q, et al. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. *Nat Commun.* 2016;7:11971.
5. Son J, Lyssiotis CA, Ying H, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. *Nature.* 2013;496:101–105.
6. Juric D, Castel P, Griffith M, et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor. *Nature.* 2015; 518:240–244.
7. Elkabets M, Pazarentzos E, Juric D, et al. AXL mediates resistance to PI3Kalpha inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. *Cancer Cell.* 2015;27:533–546.
8. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. *J Clin Invest.* 2013;123:3678–3684.
9. Gross MI, Demo SD, Dennison JB, et al. Antitumor Activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. *Mol Cancer Ther.* 2014;13:890–901.